For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its ...

Financial analysts lambasted Sarepta executives for failing to disclose a drug-test fatality when the company announced a ...

14 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Taking into account the latest results, the most recent consensus for Sarepta Therapeutics from 18 analysts is for revenues of US$624.0m in 2021 which, if met, would be a meaningful 16% increase ...

Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Intercept Pharma (ICPT – Research Report) and ...

Shares of drugmaker Sarepta Therapeutics continued to fall Tuesday after the company said it would comply with a Food and Drug Administration request to pause shipments of ...

Monday, Oppenheimer analysts lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $184 from the previous $215, while maintaining an Outperform rating on the company’s shares.The ...

TD Cowen analyst Ritu Baral maintained a Hold rating on Sarepta Therapeutics today and set a price target of $24.00. The company’s shares closed last Friday at $20.08. According to TipRanks.com ...